Johnson & Johnson Innovation and Janssen Biotech Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber’s Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen’s lung cancer discovery pipeline.

 

“We are thrilled to be working with the scientists at the Belfer Institute,” said Peter Lebowitz, Janssen Global Therapeutic area head, oncology. “Their excellence in lung cancer translational research, which incorporates both tumor genetics and immunotherapy, will be critical to the development of personalized treatment options for patients in need.” 

 

Utilizing the Belfer Institute’s proprietary immuno-oncology lung platform and lung cancer disease expertise, the research teams will also seek to identify rational immuno-oncology drug combination strategies and biomarkers, and to characterize mechanisms of resistance. The collaboration will also identify and validate novel targets for lung cancers.

 

“There is a growing recognition of the potential importance of immuno-oncology agents directed at a variety of cancers,” said Robert Urban, head of Johnson & Johnson Innovation, Boston. “Through our collaboration with the Dana-Farber Cancer Institute, we will be able to increase the probability of success and decrease development times for our important immuno-oncology pipeline in the critical area of lung cancer.”

 

Lung cancer is one of three focus areas for Janssen Oncology based on its high unmet need. According to the American Cancer Society, lung cancer is the leading cause of cancer death among both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Overall, the chance that a man will develop lung cancer in his lifetime is about one in 13; for a woman, the risk is about one in 16.

 

Date: June 24, 2014

Source: Johnson & Johnson